Norman R Wasel

Learn More
BACKGROUND Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in(More)
Tay-Sachs disease (TSD) results from mutations in HEXA that cause Hex A deficiency. Heterozygote-screening programs have been applied in groups with an increased TSD incidence, such as Ashkenazi Jews and French Canadians in Quebec. These programs are complicated by benign mutations that cause apparent Hex A deficiency but not TSD. Benign mutations account(More)
BACKGROUND Psoriasis is a chronic inflammatory disease associated with comorbidities and decreased quality of life. This survey is aimed to better understand the impact of disease on Canadian patients, and to examine awareness and use of available treatment options. METHODS An online survey was conducted using a consumer panel. Eligible subjects reported(More)
OBJECTIVE To determine the efficacy, safety, and sustainability of response to adalimumab therapy for moderate to severe chronic plaque psoriasis involving hands and/or feet. DESIGN Sixteen-week, randomized, double-blind, placebo-controlled evaluation of adalimumab therapy for moderate to severe chronic plaque psoriasis involving the hands and/or feet(More)
BACKGROUND The use of systemic calcineurin inhibitors for the treatment of patients with psoriasis is limited by toxicity, particularly nephrotoxicity. ISA247, a novel inhibitor, was effective and well tolerated in a phase II study of patients with plaque psoriasis. Therefore its efficacy was assessed in this phase III study. METHODS 451 patients aged(More)
BACKGROUND Few population studies of individuals living with psoriasis have been performed in Canada. OBJECTIVE The objective of this survey was to understand the severity and impact of psoriasis on the lives of Canadian patients. METHODS An online survey was conducted using a consumer panel. Eligible subjects reported a diagnosis of psoriasis and(More)
melanoma: a case report and review of the literature. Rheumatol Int 1999; 19 : 65–67. 7 Becker JC, Winkler B, Klingert S, et al. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994; 73 : 1621–1624. 8 Parodi A, Semino M, Gallo R, et al. Bullous eruption with circulating pemphigus-like antibodies following(More)
BACKGROUND Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life. OBJECTIVE We evaluated the efficacy and safety of apremilast in palmoplantar psoriasis. METHODS A post hoc analysis of data pooled from phase IIb (PSOR-005) and phase III (Efficacy and Safety Trial Evaluating the Effects of Apremilast in(More)
BACKGROUND Minocycline-induced cutaneous pigmentation is an adverse effect that may be more common than is generally realized. It is usually reported in patients undergoing chronic minocycline therapy for acne vulgaris. OBJECTIVE The case of a 69-year-old woman taking minocycline for rheumatoid arthritis is presented, and its differential diagnosis(More)
BACKGROUND A two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/Dovobet) has been evaluated in a large clinical trial programme, providing a wealth of data on the treatment of psoriasis vulgaris. OBJECTIVE To determine the effectiveness of the two-compound product in patients with mild, moderate and severe psoriasis(More)